I had a wonderful visit to our Biomedical Research hub in San Diego, where our scientists continue to carry out truly innovative and creative drug discovery work. Among the many people I met with were members of the engineering and data science groups from Discovery Sciences — two of the teams behind the ingenious approach that you can read about below. It’s exciting to see this work, on which they’re collaborating with teams from our Cardiovascular & Metabolism Disease Research Area, providing valuable insights in the hunt for new drugs for cardiovascular diseases. Their efforts are an excellent example of how teamwork, curiosity, and the collective desire to take on tough challenges in biomedicine drives the Novartis mission to reimagine medicine. https://lnkd.in/eHUwyveV Thierry Diagana, Scott Hammack, John Tallarico, Minhua Qiu, Edwin Raagas, Shaun Coughlin
Congratulations. Very impressive. Looking forward to the future with these technology platforms which will contribute significantly. By chance I was presenting some information on HF and SCD in guinea pig animal model. Not my work but from Joshi Pooja et al. Joshi, Pooja, et al. "Ryanodine receptor 2 inhibition reduces dispersion of cardiac repolarization, improves contractile function, and prevents sudden arrhythmic death in failing hearts." Elife 12 (2023): RP88638. https://elifesciences.org/articles/88638
Really impressive setup! The 3D posts for measuring force in a multiwell environment are exciting. Looking forward to seeing this work continue to scale.
Really a tour de force of biologically relevant assay creation! Kudos!
Amazing strides
Director at Novartis
1moFiona H. Marshall thank your for your visit and this post. Shout out on the technology side to Andrew Brady, Ton Trinh, Christopher Plunkett, Joshua Barbara, and Michael Shih for their multi-year tenacity and innovation to bring forward this particular model.